Header Logo

Connection

JASVINDER SINGH to Rheumatic Diseases

Back to Details
This is a "connection" page, showing publications JASVINDER SINGH has written about Rheumatic Diseases.
JASVINDER SINGH
Connection Strength
9.697
Rheumatic Diseases
  1. The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases. BioDrugs. 2023 Sep; 37(5):625-635.
    View in: PubMed
    Score: 0.794
  2. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2022 09; 74(9):1464-1473.
    View in: PubMed
    Score: 0.741
  3. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care Res (Hoboken). 2022 09; 74(9):1399-1408.
    View in: PubMed
    Score: 0.741
  4. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2022 09; 37(9):1676-1683.
    View in: PubMed
    Score: 0.741
  5. Management of Rheumatic Diseases During the COVID-19 Pandemic: A National Veterans Affairs Survey of Rheumatologists. Arthritis Care Res (Hoboken). 2021 07; 73(7):998-1003.
    View in: PubMed
    Score: 0.693
  6. Are the days of missed or delayed diagnosis of gout over? Nat Rev Rheumatol. 2019 10; 15(10):578-580.
    View in: PubMed
    Score: 0.614
  7. The OMERACT First-time Participant Program: Fresh Eye from the New Guys. J Rheumatol. 2017 Oct; 44(10):1560-1563.
    View in: PubMed
    Score: 0.520
  8. OMERACT 11: international consensus conference on outcome measures in rheumatology. J Rheumatol. 2014 Jan; 41(1):145-9.
    View in: PubMed
    Score: 0.412
  9. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013 Mar; 5(3):265-99.
    View in: PubMed
    Score: 0.389
  10. Effect of comorbidity on quality of life of male veterans with prevalent primary total knee arthroplasty. Clin Rheumatol. 2009 Sep; 28(9):1083-9.
    View in: PubMed
    Score: 0.299
  11. Contributions of OMERACT to rheumatic disease research. Arthritis Rheum. 2007 Feb 15; 57(1):186.
    View in: PubMed
    Score: 0.256
  12. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum. 2006 Jun 15; 55(3):348-52.
    View in: PubMed
    Score: 0.244
  13. Long-Term Mortality Following SARS-CoV-2 Infection in Rural Versus Urban Dwellers With Autoimmune or Inflammatory Rheumatic Disease: A Retrospective Cohort Analysis From the National COVID Cohort Collaborative. Arthritis Care Res (Hoboken). 2025 Jan; 77(1):143-155.
    View in: PubMed
    Score: 0.218
  14. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments. Semin Arthritis Rheum. 2024 04; 65:152344.
    View in: PubMed
    Score: 0.205
  15. Telemedicine in rheumatology care: A systematic review. Semin Arthritis Rheum. 2022 10; 56:152045.
    View in: PubMed
    Score: 0.185
  16. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021 09; 7(3).
    View in: PubMed
    Score: 0.175
  17. OMERACT 2020: A virtual (R)evolution. Semin Arthritis Rheum. 2021 06; 51(3):588-592.
    View in: PubMed
    Score: 0.171
  18. Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. J Rheumatol. 2020 10 01; 47(10):1565-1574.
    View in: PubMed
    Score: 0.156
  19. Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. J Rheumatol. 2019 10; 46(10):1355-1359.
    View in: PubMed
    Score: 0.148
  20. OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. J Rheumatol. 2019 08; 46(8):1021-1027.
    View in: PubMed
    Score: 0.147
  21. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. J Rheumatol. 2019 10; 46(10):1409-1414.
    View in: PubMed
    Score: 0.147
  22. Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. J Rheumatol. 2019 09; 46(9):1202-1206.
    View in: PubMed
    Score: 0.146
  23. Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. J Rheumatol. 2019 09; 46(9):1159-1163.
    View in: PubMed
    Score: 0.146
  24. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. J Rheumatol. 2019 08; 46(8):1053-1058.
    View in: PubMed
    Score: 0.146
  25. Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials. 2018 Mar 27; 19(1):204.
    View in: PubMed
    Score: 0.138
  26. Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. J Rheumatol. 2017 Oct; 44(10):1551-1559.
    View in: PubMed
    Score: 0.132
  27. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol. 2017 08; 69(8):1538-1551.
    View in: PubMed
    Score: 0.131
  28. Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. J Rheumatol. 2015 Dec; 42(12):2448-59.
    View in: PubMed
    Score: 0.114
  29. Updating the OMERACT filter: discrimination and feasibility. J Rheumatol. 2014 May; 41(5):1005-10.
    View in: PubMed
    Score: 0.105
  30. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of "truth": content, face, and construct validity. J Rheumatol. 2014 May; 41(5):1000-4.
    View in: PubMed
    Score: 0.105
  31. Updating the OMERACT filter: core areas as a basis for defining core outcome sets. J Rheumatol. 2014 May; 41(5):994-9.
    View in: PubMed
    Score: 0.104
  32. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. J Rheumatol. 2014 May; 41(5):1025-30.
    View in: PubMed
    Score: 0.104
  33. Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol. 2014 May; 41(5):1016-24.
    View in: PubMed
    Score: 0.104
  34. Including health equity considerations in development of instruments for rheumatology research: an introduction to a novel OMERACT paradigm. J Rheumatol. 2014 Jan; 41(1):150-2.
    View in: PubMed
    Score: 0.101
  35. Classification criteria in rheumatic diseases: a review of methodologic properties. Arthritis Rheum. 2007 Oct 15; 57(7):1119-33.
    View in: PubMed
    Score: 0.067
  36. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. J Arthroplasty. 2017 09; 32(9):2628-2638.
    View in: PubMed
    Score: 0.033
  37. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol. 2014 Jul; 67(7):745-53.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.